Cerebrolysin

Last Updated: July 2026

Cerebrolysin is a neuropeptide preparation made by controlled enzymatic hydrolysis of porcine brain proteins — roughly 25% low-molecular-weight peptide fragments (below ~10 kDa) and 75% free amino acids. It is not a single molecule but a defined mixture, and its peptide fraction is thought to mimic endogenous neurotrophic factors. It is approved for stroke, traumatic brain injury, and dementia in many European and Asian countries (marketed by EVER Neuro Pharma), but is not FDA-approved and is treated as investigational in the US.

What is Cerebrolysin and how does it work?

Cerebrolysin's low-molecular-weight peptides can cross the blood-brain barrier and are reported to mimic or stimulate neurotrophic factors — upregulating BDNF, NGF, IGF-1, and VEGF and engaging Trk-receptor signaling (MAPK/ERK, PI3K/Akt) — which supports neuronal survival, neuroplasticity, and neurogenesis. Because it is a mixture, its activity is attributed to the peptide fraction as a whole rather than one active compound.

What does the clinical evidence actually show?

This is where honesty matters: Cerebrolysin is far better studied than a typical research peptide — it has real randomized controlled trials and Cochrane systematic reviews — but the independent verdict is mixed, ranging from no convincing benefit (with a possible harm signal) in stroke to suggestive-but-not-definitive in dementia, and Cochrane rated overall evidence quality as low due to small samples and bias. Some meta-analyses report benefit (e.g. cognitive improvement in dementia at four weeks; reduced mortality/disability in severely affected stroke patients), but the highest-quality reviews counsel caution. Evidence level: Approved in many countries + RCTs, but independent evidence quality is low/mixed.

What are the safety and regulatory considerations?

Cerebrolysin has a long clinical track record and an established tolerability profile in its approved markets, but it is not FDA-approved, and material sold through research-chemical channels is not the approved pharmaceutical. See the legal status guide.

Why does vendor verification matter, and how does Peptigrity verify?

Because Cerebrolysin is a biologically-sourced mixture rather than a defined molecule, it can't be verified by a single expected mass — purity, composition, and absence of contaminants (via HPLC and appropriate methods) are the relevant checks, and provenance matters for an animal-derived product. Peptigrity buys it anonymously, tests it at independent ISO-accredited labs, and publishes the unedited COA; the trust score weights lab purity and reviews equally (50/50). See how to read lab results.

Educational information only; not medical advice. Cerebrolysin is not FDA-approved. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.